BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 15510175)

  • 41. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats.
    Faivre J; Clerc J; Gérolami R; Hervé J; Longuet M; Liu B; Roux J; Moal F; Perricaudet M; Bréchot C
    Cancer Res; 2004 Nov; 64(21):8045-51. PubMed ID: 15520214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter.
    Tanaka S; Iwai M; Harada Y; Morikawa T; Muramatsu A; Mori T; Okanoue T; Kashima K; Maruyama-Tabata H; Hirai H; Satoh E; Imanishi J; Mazda O
    Cancer Gene Ther; 2000 Sep; 7(9):1241-50. PubMed ID: 11023196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feasibility of a novel positive feedback effect of 131I-promoted Bac-Egr1-hNIS expression in malignant glioma through baculovirus: a comparative study with Bac-CMV-hNIS.
    Guo R; Zhang R; Pan Y; Xu H; Zhang M; Liang S; Wang L; Zhang Y; Li B
    Nucl Med Commun; 2011 May; 32(5):402-9. PubMed ID: 21386735
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of sodium/iodide symporter (NIS)-mediated radioiodine therapy on estrogen receptor-negative breast cancer.
    Yao C; Pan Y; Li Y; Xu X; Lin Y; Wang W; Wang S
    Oncol Rep; 2015 Jul; 34(1):59-66. PubMed ID: 25955347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells.
    Haberkorn U; Beuter P; Kübler W; Eskerski H; Eisenhut M; Kinscherf R; Zitzmann S; Strauss LG; Dimitrakopoulou-Strauss A; Altmann A
    J Nucl Med; 2004 May; 45(5):827-33. PubMed ID: 15136633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene therapy with sodium/iodide symporter in hepatocarcinoma.
    Haberkorn U
    Exp Clin Endocrinol Diabetes; 2001; 109(1):60-2. PubMed ID: 11573143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene.
    Mandell RB; Mandell LZ; Link CJ
    Cancer Res; 1999 Feb; 59(3):661-8. PubMed ID: 9973215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose.
    Haberkorn U; Kinscherf R; Kissel M; Kübler W; Mahmut M; Sieger S; Eisenhut M; Peschke P; Altmann A
    Gene Ther; 2003 May; 10(9):774-80. PubMed ID: 12704416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.
    Carlin S; Akabani G; Zalutsky MR
    J Nucl Med; 2003 Nov; 44(11):1827-38. PubMed ID: 14602867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adenovirus-mediated and tumor-specific transgene expression of the sodium-iodide symporter from the human telomerase reverse transcriptase promoter enhances killing of lung cancer cell line in vitro.
    Shi YZ; Zhang J; Liu ZL; Du SY; Shen YM
    Chin Med J (Engl); 2010 Aug; 123(15):2070-6. PubMed ID: 20819544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy.
    Kang JH; Chung JK; Lee YJ; Shin JH; Jeong JM; Lee DS; Lee MC
    J Nucl Med; 2004 Sep; 45(9):1571-6. PubMed ID: 15347726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.
    Willhauck MJ; Sharif-Samani B; Senekowitsch-Schmidtke R; Wunderlich N; Göke B; Morris JC; Spitzweg C
    Breast Cancer Res Treat; 2008 May; 109(2):263-72. PubMed ID: 17636401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene.
    Raben D; Buchsbaum DJ; Khazaeli MB; Rosenfeld ME; Gillespie GY; Grizzle WE; Liu T; Curiel DT
    Gene Ther; 1996 Jul; 3(7):567-80. PubMed ID: 8818643
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS.
    Wenzel A; Upadhyay G; Schmitt TL; Loos U
    Mol Cell Endocrinol; 2003 Dec; 213(1):99-108. PubMed ID: 15062578
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells.
    Unterholzner S; Willhauck MJ; Cengic N; Schütz M; Göke B; Morris JC; Spitzweg C
    J Clin Endocrinol Metab; 2006 Jan; 91(1):69-78. PubMed ID: 16234306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human sodium iodide symporter added to multidrug resistance 1 small hairpin RNA in a single gene construct enhances the therapeutic effects of radioiodine in a nude mouse model of multidrug resistant colon cancer.
    Jeon YH; Ahn SJ; Lee YJ; Lee YL; Lee SW; Park SY; Kim IS; Ahn BC; Ha JH; Lee J
    Cancer Biother Radiopharm; 2010 Dec; 25(6):671-9. PubMed ID: 21204761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Telomerase reverse transcriptase promoter-driven expression of iodine pump genes for targeted radioiodine therapy of malignant glioma cells.
    Tan J; Li W; Wang P
    Chin J Cancer; 2011 Aug; 30(8):574-80. PubMed ID: 21801606
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter.
    Kim HJ; Jeon YH; Kang JH; Lee YJ; Kim KI; Chung HK; Jeong JM; Lee DS; Lee MC; Chung JK
    Cancer Biol Ther; 2007 Jul; 6(7):1130-5. PubMed ID: 17611400
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I.
    Tang J; Wang X; Xu Y; Shi Y; Liu Z; Yang Y
    Technol Cancer Res Treat; 2015 Feb; 14(1):61-9. PubMed ID: 24354753
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined RNA interference of hexokinase II and (131)I-sodium iodide symporter gene therapy for anaplastic thyroid carcinoma.
    Kim JE; Ahn BC; Hwang MH; Jeon YH; Jeong SY; Lee SW; Lee J
    J Nucl Med; 2011 Nov; 52(11):1756-63. PubMed ID: 21994409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.